Silk Road Medical IncSILK posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased TCAR adoption, beating the consensus of $31.16 million.
“We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility,” said Erica Rogers, CEO
“We also gained meaningful market share through strong physician utilization as we continue to establish TCAR as the minimally-invasive standard of care in stroke prevention, evidenced by recently eclipsing 50,000 global TCAR procedures,” Rogers added.
Gross margin declined to 73% from 75%, impacted by continued manufacturing expansion costs at the new Minnesota facility.
EPS loss reached $(0.44) compared to $(0.31) a year ago, beating the consensus of $(0.46).
Guidance: Silk Road Medical projects FY22 revenue of $128 million – $133 million versus the consensus of $129.32 million.
Price Action: SILK shares traded 2.13% higher at $44.06 on the last check Wednesday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
